Carglumic Acid
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Methylmalonic Acidemia
Conditions
Methylmalonic Acidemia, Propionic Acidemia
Trial Timeline
Jan 15, 2019 → Jul 30, 2029
NCT ID
NCT04176523About Carglumic Acid
Carglumic Acid is a pre-clinical stage product being developed by Recordati for Methylmalonic Acidemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04176523. Target conditions include Methylmalonic Acidemia, Propionic Acidemia.
Hype Score Breakdown
Clinical
3
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05040178 | Pre-clinical | Recruiting |
| NCT04176523 | Pre-clinical | Recruiting |
Competing Products
4 competing products in Methylmalonic Acidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-3705 | Moderna | Phase 2 | 0 |
| "The MaP Study": Mapping the Patient Journey in MMA and PA | Moderna | Preclinical | 0 |
| mRNA-3704 | Moderna | Phase 2 | 0 |
| mRNA-3705 | Moderna | Phase 2 | 0 |